REG - Cizzle Biotechnology - Appointment of Non-Executive Director

Cizzle Biotechnology HoldingsAnnouncement

25/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250325:nRSY9506Ba&default-theme=true

RNS Number : 9506B  Cizzle Biotechnology Holdings PLC  25 March 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR").

25 March 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Appointment of Non-Executive Director

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests
is pleased to announce the appointment of Edwin Matthew (Matt) Bower as a
Non-Executive Director ("NED") of the Company with immediate effect.

 

Matt Bower is an experienced company executive and adviser with a track record
as a director and secretary of private equity backed and listed companies,
across a broad range of company and technology related activities. He is
engaged as a strategic advisor and mentor to the board of directors of a
number of high growth trading and technology companies, and a director of a
number of private companies.

 

Matt will sit on both the Company's audit and remuneration committees,
alongside the Company's independent Non-Executive Director, John Treacy,
replacing Prof Dawn Coverley who recently moved from her role as a NED to
Chief Scientific Officer, as announced on 2 January 2025.

 

Matt is a Director of Makabo Limited ("Makabo"), a strategic consultancy and
board advisory business.  On the 24 June 2024, the Company entered into an
agreement (the "Agreement") with Makabo to support the Board in the areas of
strategy, partnerships, licensing and shareholder communications. With Matt
joining the Board, the Agreement has now been terminated.  Pursuant to the
Agreement, Makabo waived payment of more than 85 per cent of its contracted
fees to link remuneration directly to the success of the Company, by accepting
2,464,625 options over new Ordinary Shares (the "Options") with an exercise
price of 1.622965p per ordinary share. The Options were granted on a pro-rata
monthly basis and will all vest and become exercisable on 25 June 2025
assuming that the VWAP of the Ordinary Shares for the period 25 May 2025 to 24
June 2025 is equal or greater than 3.24593p, being twice or greater than the
Options grant price. The Options remain exercisable until 25 June 2027.

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

 

"I am delighted to welcome Matt to the board, which will strengthen our
strategic and business capability and meet our needs for a further NED to
support the Company's corporate governance requirements.  Matt has already
provided valuable advice and assistance to Cizzle and I am sure that his
skills and experience will be invaluable as we move forward.

 

"This is a transformational period as the Company prepares for the commercial
launch of its lung cancer test in North America and the Caribbean with our
partner CizzleBio Inc and future roll out with partner laboratories elsewhere
in the world, where Matt's international experience and strategic advice will
be of particular help as we begin the next phase of our growth."

Other than as set out in this announcement there are no further disclosures
required in respect of Edwin Matthew Bower under paragraph 9.6.13 of the
Listing Rules.

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited                                     +44(0) 20 3328 5656
 John Depasquale/Piers Shimwell (Corporate Finance)
 Stefano Aquilino/Amrit Nahal (Sales and Corporate Broking)

 

 IFC Advisory Limited            +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a
naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B
biomarker is highly associated with the presence of early-stage cancer. The
company has developed CIZ1B into a non-invasive, cost-effective blood test to
help in the early detection of lung cancer and has now entered into commercial
royalty-bearing arrangements to license its proprietary technology, and into
collaborations with centres of excellence in cancer care.  Cizzle was
admitted to the Standard segment of the main market of the London Stock
Exchange in May 2021.

 

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZGZFNDKGKZM